We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Lokal İleri Evre Özefagus Kanserinde Kemoradyoterapi Deneyimimiz.
- Authors
ALSAN ÇETİN, İlknur; ÖNCÜ YUMUK, P. Fulden; ATASOY, Beste M.; DANE, Faysal; Başak ÇAĞLAR, Hale; İBRAHİMOV, Roman; Fevzi BATIREL, Hasan; ABACIOĞLU, Ufuk
- Abstract
Objective: In this study, we report our neoadjuvant/definitive chemoradiotherapy (CRT) experience in locally advanced esophageal cancer patients. Patients and Methods: A total of 15 patients were retrospectively evaluated. Histological diagnosis were as follows: squamous cell 10, adenocarcinoma 4, adenosquamous carcinoma1. Initial stage was T3N0M0 5 or T3N1M0/T4N0M0 10. Radiotherapy was administered at median of 50 Gy (1.8-2 Gy/day, 5 fractions/week) and cisplatin and 5-fluorouracil were given concurrently on the first and the last week of radiotherapy. Results: Continuous applicability of concurrent chemoradiotherapy was 80%. Median follow-up was 15 months (range, 3-70 months). One of the five patients who were treated with neoadjuvant approach had local progression, and three had distant metastasis. Three patients (30%) who were planned to be treated with definitive CRT had downstaging and surgery was recommended. Two-year local control rate was 22%, distant metastasis-free survival rate was 45% and overall survival rate was 31%. Grade III dysphagia was observed in 6% of patients. Conclusion: Treatment of locally advanced esophageal cancer remains controversial. Although patients who had surgery were reported to have longer survival and better local control rates, the feasibility of triple-modality treatment is limited to the center's experience. For this reason, all patients should be evaluated individually with a multidisciplinary approach.
- Subjects
ESOPHAGEAL tumors; CANCER chemotherapy; RADIOTHERAPY; RETROSPECTIVE studies; TUMOR treatment
- Publication
Marmara Medical Journal, 2012, Vol 25, Issue 2, p74
- ISSN
1019-1941
- Publication type
Article
- DOI
10.5472/MMJ.2011.02200.1